Abstract
Elevated nighttime blood pressure (BP) and a reduced day-night BP fall ("nondipping" condition) are strong predictors of cardiovascular complications, both in hypertension and in the general population. A reduced or inverted nocturnal BP fall might also be theoretically used to define the most appropriate timing for drug administration. In a systematic review of the available evidence, we show that bedtime dosing of antihypertensive medication reduces nocturnal BP and increases day-night BP fall more than standard morning dosing. The effects of such an approach on average 24-hour BP are more modest and less univocal, with a considerable betweencenter heterogeneity. Admittedly, the mechanisms underlying non-dipping condition have not been fully understood yet, and it is still a matter of debate whether restorating a dipping pattern may reduce the cardiovascular risk associated with non-dipping independently from the effects on 24-hour BP. Under this regard, evidence from a single trial strongly suggests that bedtime dosing of antihypertensive medications may greatly reduce cardiovascular morbidity in hypertensive patients. The provocative results of that trial deserve to be explored further in larger intervention trials.
Keywords: Hypertension, treatment, chronotherapy, nocturnal blood pressure, dipping.
Current Pharmaceutical Design
Title:Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Volume: 21 Issue: 6
Author(s): Giuseppe Schillaci, Francesca Battista, Laura Settimi and Luca Schillaci
Affiliation:
Keywords: Hypertension, treatment, chronotherapy, nocturnal blood pressure, dipping.
Abstract: Elevated nighttime blood pressure (BP) and a reduced day-night BP fall ("nondipping" condition) are strong predictors of cardiovascular complications, both in hypertension and in the general population. A reduced or inverted nocturnal BP fall might also be theoretically used to define the most appropriate timing for drug administration. In a systematic review of the available evidence, we show that bedtime dosing of antihypertensive medication reduces nocturnal BP and increases day-night BP fall more than standard morning dosing. The effects of such an approach on average 24-hour BP are more modest and less univocal, with a considerable betweencenter heterogeneity. Admittedly, the mechanisms underlying non-dipping condition have not been fully understood yet, and it is still a matter of debate whether restorating a dipping pattern may reduce the cardiovascular risk associated with non-dipping independently from the effects on 24-hour BP. Under this regard, evidence from a single trial strongly suggests that bedtime dosing of antihypertensive medications may greatly reduce cardiovascular morbidity in hypertensive patients. The provocative results of that trial deserve to be explored further in larger intervention trials.
Export Options
About this article
Cite this article as:
Schillaci Giuseppe, Battista Francesca, Settimi Laura and Schillaci Luca, Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension, Current Pharmaceutical Design 2015; 21 (6) . https://dx.doi.org/10.2174/1381612820666141024130013
DOI https://dx.doi.org/10.2174/1381612820666141024130013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Psychosocial Factors and Diabetes Mellitus: Evidence-Based Treatment Guidelines
Current Diabetes Reviews Development of Gene Therapies for Cardiovascular and Renal Diseases by Nucleic Acid Medicines
Medicinal Chemistry PEDF in Angiogenic Eye Diseases
Current Molecular Medicine Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Involvement of Orexigenic Peptides in the Mechanism of Gastric Mucosal Integrity and Healing of Chronic Gastric Ulcers
Current Pharmaceutical Design Association Between the Levels of Circulating Adhesion Molecules and Biopterins in Type-2 Diabetic Normotensive Patients Adhesion Molecules and Biopterins
Endocrine, Metabolic & Immune Disorders - Drug Targets Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis
Medicinal Chemistry Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design Molecular Docking, DFT Studies and ADMET Simulations for Evaluating Already Approved FDA Drugs as Inhibitors for SARS-Cov-2 RNADependent Polymerase
Letters in Drug Design & Discovery Vascular Endothelial Dysfunction and Nutritional Compounds in Early Type 1 Diabetes
Current Diabetes Reviews Histopathology of Connective Tissue Disease-Associated Pleuropulmonary Disease
Current Respiratory Medicine Reviews Editorial [Hot Topic: Murine Atherosclerosis (Part II) (Guest Editor: Godfrey S. Getz)]
Current Drug Targets Polyphenols Regulate Endothelial Functions and Reduce the Risk of Cardiovascular Disease
Current Pharmaceutical Design Nociceptin/Orphanin FQ Peptide Receptor as a Therapeutic Target for Obesity
Mini-Reviews in Medicinal Chemistry Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration
Current Drug Targets The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets
Current Medicinal Chemistry Technology for the Production and Utilization of Food Protein-Derived Antihypertensive Peptides: A Review
Recent Patents on Biotechnology Thalidomide Controls Adipose Tissue Inflammation Associated with High- Fat Diet-Induced Obesity in Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews